InflaRx Reports Third Quarter 2022 Financial & Operating Results
November 09, 2022 07:30 ET
|
InflaRx N.V.
Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S....
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
September 08, 2022 07:30 ET
|
InflaRx N.V.
The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in...
InflaRx Reports Second Quarter 2022 Financial & Operating Results
August 05, 2022 07:00 ET
|
InflaRx N.V.
Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients...
InflaRx to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
March 31, 2022 07:30 ET
|
InflaRx N.V.
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary...
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
March 08, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
January 10, 2022 07:30 ET
|
InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...
Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
December 10, 2019 08:00 ET
|
Navigen, Inc.
SALT LAKE CITY, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Navigen, Inc. announced today that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug application ("IND") for...